Imagine losing a lifeline that finally helped you conquer a lifelong battle with weight—only to have it snatched away due to insurance changes. This is the harsh reality for thousands of patients relying on GLP-1 weight-loss drugs. For many, these medications aren’t just about shedding pounds; they’re about reclaiming health, reversing prediabetes, and reducing the risk of life-threatening conditions like heart disease. But here’s where it gets controversial: insurers are dropping coverage, leaving patients scrambling to afford these life-changing treatments out of pocket.
Take the case of Tierno, who credits GLP-1 drug Zepbound for helping him overcome weight gain that wasn’t just a matter of willpower but a chemical imbalance. “It gave my body the biological help it needed,” he said. Yet, Tierno is one of over 40,000 customers from Massachusetts’ two largest insurers, Blue Cross and Point32Health, who lost coverage for GLP-1s this year. And this is the part most people miss: the Group Insurance Commission, covering over 460,000 state employees and relatives, recently voted to end coverage, with MassHealth potentially following suit. In 2024 alone, about 140,400 patients with obesity in Massachusetts were prescribed these medications, including brands like Zepbound, Wegovy, Ozempic, and Mounjaro.
For those who’ve spent years—even decades—struggling with weight, this change feels like a betrayal. Michelle Markert, a 55-year-old interior designer, lost 35 pounds on GLP-1s before her insurer pulled the plug. Now, she faces a $500 monthly bill, equivalent to a car payment. “I don’t take this medicine for fun,” she said. “I take it because I need it.” Her story isn’t unique; countless others are now forced to choose between paying for the drugs or cutting back on essentials like dining out or entertainment.
But why are insurers dropping coverage? They point fingers at pharmaceutical giants Eli Lilly and Novo Nordisk, accusing them of charging exorbitant prices. For instance, Zepbound and Wegovy can cost between $900 to over $1,300 a month. Blue Cross alone spent $515 million on GLP-1s in 2025, up from $140 million in 2023. Insurers argue these costs are unsustainable, but patients and doctors counter that the long-term health benefits—like reducing obesity-related complications—far outweigh the price tag.
Dr. Paul Copeland, an obesity specialist at Massachusetts General Hospital, warns of the dangers of discontinuing these medications. “Not only is there rapid weight regain, but comorbidities like cardiovascular risk factors worsen,” he said. Some of his patients have already started regaining weight, and he fears for their health. A recent study predicts that most patients will regain lost weight within 18 months of stopping GLP-1s.
The situation has sparked a debate about equity. Direct-to-consumer programs like NovoCare and LillyDirect offer alternatives, but prices range from $149 to $449 a month—still out of reach for many. “It’s creating a two-tier system,” Dr. Copeland noted, where only those who can afford it maintain access.
Insurers argue that lowering drug prices is the key to restoring coverage. Novo Nordisk recently announced plans to cut GLP-1 prices by up to half in 2027, citing pressure from payers and patients. But Eli Lilly has shown no such willingness, leaving many patients in limbo.
Robert Atterbury, a 60-year-old audiology coordinator, lost 20 pounds on GLP-1s but can’t afford the $300 monthly cost without insurance. His weight is creeping back up, and he’s worried about his health. “The drug company and the insurer made the decision for me,” he said. “I had nothing to do with it except not making enough to pay for it.”
Susan Elsbree, a public relations executive, is equally frustrated. After losing 35 pounds and improving her health, she’s now paying $199 a month out of pocket. “This is about equity,” she said. “The gap between the haves and have-nots is widening.”
Here’s the burning question: Should insurers prioritize short-term costs over long-term health benefits? And should pharmaceutical companies lower prices to ensure these life-changing drugs remain accessible? Let us know your thoughts in the comments—this debate is far from over.
